Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Correlation of surgical volume in gynecological cancer centers with the quality of ovarian cancer care.","authors":"Olaf Ortmann, Rebecca Roth, Birgit Klages, Christoph Kowalski, Johannes Bruns, Pauline Wimberger, Jalid Sehouli, Matthias W Beckmann, Susanne Schüler-Toprak","doi":"10.1007/s00432-025-06288-6","DOIUrl":"10.1007/s00432-025-06288-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"239"},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review on the impact of delayed local therapy in patients with Ewing sarcoma of the pelvis.","authors":"Shook Fe Yap, Natacha Omer, Vivek Bhadri, Jeremy Lewin, Wayne Nicholls, Claire Carkeet, Lisa Orme, Marianne Phillips, Mark Winstanley, Smaro Lazarakis, Jasmine Mar, Angela Hong, Julie Cayrol","doi":"10.1007/s00432-025-06286-8","DOIUrl":"10.1007/s00432-025-06286-8","url":null,"abstract":"<p><strong>Background: </strong>Local treatment of pelvic Ewing Sarcoma (EWS) is czhallenging due to complex anatomy and potential complications. Local therapy may be deferred to maintain chemotherapy dose-intensity, but the impact of this delay on outcomes remains unclear.</p><p><strong>Methods: </strong>A systematic review using the PICO model evaluated whether delayed local therapy affects long-term outcomes in localized pelvic EWS. Ovid Medline, Ovid Embase, and Cochrane Central databases were searched through June 2024. Studies were screened by two independent reviewers for quantitative and qualitative data extraction.</p><p><strong>Results: </strong>Of 1849 studies screened, eight eligible studies including 2618 patients were identified; none were pelvic-specific. When specified, 1-18% had pelvic primaries. All studies were retrospective with substantial heterogeneity in endpoints. Seven of eight studies indicated delayed local therapy was associated with reduced event-free survival (EFS) and/or overall survival (OS). In the largest study (Lin et al.) of 1319 EWS patients, delayed local therapy > 16 weeks was associated with significantly reduced OS (HR 1.41, CI 1.11-1.80, p = 0.005).</p><p><strong>Conclusion: </strong>This systematic review highlights the importance of multidisciplinary coordinated care during initial chemotherapy to optimize local therapy timing, which may impact outcomes. Further studies are needed to assess timing significance, particularly for pelvic EWS.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"237"},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DHRS9 promotes malignant progression of ovarian cancer through SQSTM1.","authors":"Yanju Wu, Shu Meng, Haoqi Zhao, Bowen Tan, Jinte Gao, Jingyi Du, Xiaona Meng","doi":"10.1007/s00432-025-06290-y","DOIUrl":"10.1007/s00432-025-06290-y","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"236"},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review.","authors":"Yu Gan, Qi Hu, Fangfang Hu, Shugui Wu","doi":"10.1007/s00432-025-06284-w","DOIUrl":"10.1007/s00432-025-06284-w","url":null,"abstract":"<p><strong>Background: </strong>SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT) is a rare and highly aggressive malignancy characterized by early distant metastasis and a poor prognosis, with a median overall survival (OS) of only 4-7 months. Traditional therapies offer limited benefit, while emerging data suggest the efficacy of combined immunotherapy, chemotherapy, and anti-angiogenic approaches. We report a case of a 52-year-old male with a heavy smoking history who presented with loss of consciousness and limb convulsions. Imaging revealed brain metastasis and a thoracic tumor. After surgical removal of the brain lesion and a lung biopsy, the patient was diagnosed with SMARCA4-UT, showing no targetable driver mutations and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) < 1%. The patient underwent first-line treatment with tislelizumab, bevacizumab, carboplatin, and paclitaxel. Despite discontinuation of bevacizumab due to a tumor cavity, the patient achieved partial remission (PR) after six cycles. Notably, consolidative thoracic radiotherapy (TRT) was administered following systemic disease control to enhance local control. After 5 months of maintenance therapy, oligoprogression of the primary lung lesion was detected and the progression-free survival (PFS) of first-line treatment reached 14 months. The patient then performed salvage surgery for local lesion and continued with maintenance treatment. As of May 2025, the patient has survived for 31 months since the initial diagnosis.</p><p><strong>Conclusion: </strong>Multimodal therapy integrating chemoimmunotherapy, anti-angiogenesis, consolidative radiotherapy, and salvage surgery achieved durable survival in SMARCA4-UT with brain metastasis. It highlights the potential of combining systemic and local therapies, providing valuable insights for managing this challenging disease.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"234"},"PeriodicalIF":2.8,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia.","authors":"Anna Sophia Gottschlich, Jana Ernst, Till Milde, Bernd Gruhn","doi":"10.1007/s00432-025-06289-5","DOIUrl":"10.1007/s00432-025-06289-5","url":null,"abstract":"<p><strong>Purpose: </strong>Invasive fungal diseases (IFDs) are a significant cause of morbidity and mortality in pediatric patients with hematologic malignancies including acute leukemia. Our study aimed to compare the efficacy of liposomal amphotericin B (L-AMB), posaconazole or micafungin as primary antifungal prophylaxis (PAP) in pediatric patients with acute leukemia.</p><p><strong>Methods: </strong>This retrospective observational study enrolled 95 pediatric patients with acute lymphoblastic leukemia (n = 70) or acute myeloid leukemia (n = 25), undergoing chemotherapy, including those undergoing allogeneic hematopoietic stem cell transplantation at the Department of Pediatrics, Jena University Hospital, Jena, Germany. PAP regimens included L-AMB (1 mg/kg/day or 3 mg/kg twice weekly, intravenously), posaconazole (100-300 mg/day, according to blood concentration, orally or intravenously) and micafungin (1 mg/kg/day or 3 mg/kg twice weekly, intravenously). Thirty-four patients (35.8%) received L-AMB, 37 patients (38.9%) received posaconazole, and 24 patients (25.3%) received micafungin. Patients with a history of IFD or concurrent or changing PAP were excluded. The primary endpoint was the occurrence of breakthrough IFD, while secondary endpoint included IFD-free survival. Statistical analyses were performed using Kaplan-Meier survival analysis, Gray's test and Cox regression to evaluate IFD-free survival.</p><p><strong>Results: </strong>The overall incidence of IFD was 14.7% (14 of 95 patients). IFD developed in 10 of 33 patients (29.4%) receiving L-AMB, in 4 of 38 (10.8%) patients receiving posaconazole and in none of the patients receiving micafungin. IFD-free survival was 70.6% in the L-AMB group, 89.2% in the posaconazole group and 100% in the micafungin group (p = 0.005, log-rank test). Significant differences were also observed in the cumulative incidences of breakthrough IFDs (p = 0.006) assessed by Gray's test. In multivariate Cox analysis, dichotomized prophylaxis regimes (posaconazole or micafungin vs. L-AMB) were independently associated with a reduced risk of IFD (HR = 0.244; 95% CI 0.076-0.777; p = 0.017). Age ≥ 10 years predicted inferior IFD-free survival (HR = 3.665; 95% CI 1.224-10.980; p = 0.020).</p><p><strong>Conclusion: </strong>We found a significant difference in efficacy between the three antifungal prophylaxis regimens. In our study, micafungin achieved the lowest IFD breakthrough rate. However, multicenter clinical studies would be needed to confirm the results.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"235"},"PeriodicalIF":2.8,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research and development prospects of TRIM65.","authors":"Nian-Hua Deng, Jie-Hai Chen, Zhen Tian, Shou-Bo Quan","doi":"10.1007/s00432-025-06285-9","DOIUrl":"10.1007/s00432-025-06285-9","url":null,"abstract":"<p><p>Ubiquitination, the prevalent posttranslational modification, plays a crucial role in regulating protein function, localization, and degradation within cellular environments. As an E3 ubiquitin ligase, TRIM65 has been shown in various studies to facilitate the ubiquitination of specific substrates, thereby controlling inflammation, innate immune responses, cell proliferation, apoptosis, and tumor progression. Given the multifaceted and significant role of TRIM65, this review compiles existing research on TRIM65 and lays the groundwork for future studies aimed at uncovering the mechanisms of TRIM65. Further understanding of TRIM65's interactions with its substrate proteins will offer valuable insights into the molecular underpinnings of certain diseases. Additionally, by identifying small molecules or inhibitors that target TRIM65, we may be able to develop novel drugs that modulate its activity. Such research could lead to more precise and effective treatments for conditions such as chronic inflammation, autoimmune diseases, and cancer. In summary, the study of TRIM65 not only enhances our understanding of fundamental cellular processes but also opens up new perspectives and avenues for the development of innovative therapies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"232"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.","authors":"Patrycja Królewska-Daszczyńska, Aleksandra Englisz, Maria-Laura Morawiec, Joanna Miśkiewicz, Maciej Gołębski, Aleksandra Mielczarek-Palacz","doi":"10.1007/s00432-025-06271-1","DOIUrl":"10.1007/s00432-025-06271-1","url":null,"abstract":"<p><p>Breast cancer is a heterogeneous disease, which is still a challenge for modern cancer diagnostics. Despite significant progress in diagnosis, monitoring and treatment of breast cancer, it remains the leading cause of cancer-related death in women. Effective screening methods, which enable early diagnosis of the disease and rapid personalised treatment are crucial to improving survival of women with breast cancer. In recent years, increasing attention has been paid to the clinical utility of circulating biomarkers, such as proteins, autoantibodies, miRNAs, circRNAs, ctDNA or CTCs, which have the potential to supplement traditional methods of BC diagnosis. Despite much research, no sufficiently sensitive and minimally invasive marker has been identified to aid in the early diagnosis, monitoring of disease progression and response to therapy in women with breast cancer. Combinatorial analysis of circulating biomarkers is novel and promising approach, which may overcome the limitations of single biomarker assays.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"233"},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global research landscape of retinoblastoma biomarkers: a multidisciplinary bibliometric analysis based on multiple databases (2005-2025).","authors":"Zhixin Peng, Qi Hu, Xiangdong Chen","doi":"10.1007/s00432-025-06279-7","DOIUrl":"10.1007/s00432-025-06279-7","url":null,"abstract":"<p><strong>Objective: </strong>Research exploring biomarkers for retinoblastoma (RB) diagnosis exists; however, their specific impact on RB has not been thoroughly investigated through systematic quantitative analysis. This study aims to analyze the research landscape and hotspots of RB biomarkers from 2005 to 2025, providing a theoretical reference for future investigations.</p><p><strong>Methods: </strong>We retrieved publications from the Web of Science and Scopus databases published between 2005 and 2025, followed by analysis using R software, VOSviewer, and CiteSpace tools.</p><p><strong>Results: </strong>From 2005 to 2025, annual publication output exhibited a steady upward trajectory, with notably accelerated growth observed between 2013 and 2021, followed by a moderated pace from 2021 to 2024. China led in publication volume, followed by the United States, India, and Italy. While China dominated in quantitative output, the United States established a broader network of international collaborations. Cancers emerged as the journal with the highest publication count, whereas Cancer Research ranked first in citation frequency. Current research hotspots primarily include: liquid biopsy and circulating tumor biomarkers; molecular subtyping and tumor heterogeneity; targeted therapies and drug resistance mechanisms; tumor microenvironment and immune evasion; and artificial intelligence with multimodal data integration. Investigations into RB biomarkers focus on: (1) dynamically reflecting tumor burden (short half-life properties); (2) regulating oncogene transcription/translation (targeting E2F3, PI3K, and m6A); (3) driving epithelial-mesenchymal transition (EMT) and cellular proliferation; (4) mediating immune evasion; and (5) deep learning-based identification of tumor heterogeneity. The exploration of biomarkers to optimize individualized retinoblastoma treatment has emerged as a notable research trend.</p><p><strong>Conclusion: </strong>As an emerging tool for achieving personalized therapeutic optimization, biomarkers have garnered significant attention from global scholars and are poised to become a major focus in future research on the management of RB. This study systematically reviewed and analyzed the current research landscape and key issues surrounding RB biomarkers, aiming to provide valuable references and insights for subsequent research in this field.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"231"},"PeriodicalIF":2.8,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.","authors":"Xiao Wu, Ke Fang, Wenya Huang, Gang Chen, Dingkun Wang","doi":"10.1007/s00432-025-06283-x","DOIUrl":"10.1007/s00432-025-06283-x","url":null,"abstract":"<p><p>Combined small-cell lung carcinoma (C-SCLC) is an uncommon lung cancer variant characterized by the presence of multiple pathological types within a single case or tumor, typically associated with poor outcomes. The high rate of misdiagnosis and low rate of accurate diagnosis for C-SCLC stem from limitations in sample collection, which primarily involves bronchoscopy and aspiration biopsy instead of surgical resection or autopsy. Moreover, standard chemotherapy for patients with C-SCLC has not yet been established. Cases of combined small-cell lung cancer with adenocarcinoma are extremely rare. Herein, we report a case of the detailed whole-process treatment of combined small-cell lung cancer with adenocarcinoma and review the literature.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"230"},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of paraoxonase 2 (PON2) as a potential biomarker and therapeutic target in cancer treatment.","authors":"Vinayak Agarwal, Matthew Cheesman, Alison Haywood, Sohil Khan, Shailendra Anoopkumar Dukie","doi":"10.1007/s00432-025-06282-y","DOIUrl":"10.1007/s00432-025-06282-y","url":null,"abstract":"<p><strong>Purpose: </strong>Paraoxonase 2 (PON2), a mitochondrial antioxidant enzyme, is widely expressed across body tissues and plays vital roles in cellular defence. Growing evidence links its dysregulation to oxidative stress and cancer progression. This narrative review aims to elucidate PON2's enzymatic characteristics and explore its potential modulation as an innovative therapeutic avenue for combating cancer.</p><p><strong>Methods: </strong>This narrative review provides a comprehensive evaluation of the roles of paraoxonase 2 in cancer, with a focus on its regulatory mechanisms and potential utility as a biomarker for targeted therapeutic interventions. A comprehensive analysis of the scientific literature from 1924 to 2024 was carried out, with studies retrieved from PubMed, Web of Science, and Scopus. Following a comprehensive screening process, 27 studies were included in the review.</p><p><strong>Results: </strong>The outcomes underscore PON2's complex involvement in cancer biology, spanning tumour initiation, progression, and therapeutic resistance. The antioxidant attributes of PON2 play a critical role in helping cancer cells combat chemotherapy by allowing them to sustain oxidative stress. PON2 regulates essential features of the cancer cell lifecycle, such as invasion, migration, and proliferation. Its impact on apoptosis makes it promising as a biomarker for prognosis and diagnostics as well as a therapeutic target, especially for patients with drug-resistant cancers.</p><p><strong>Conclusion: </strong>This review highlights PON2's involvement in carcinogenesis in detail. Future research should focus on elucidating the molecular mechanisms regulating PON2 and exploring its potential as a target for the development of effective cancer therapies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"229"},"PeriodicalIF":2.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}